Cathy R. Smith - 02 Mar 2026 Form 4 Insider Report for BOSTON SCIENTIFIC CORP (BSX)

Role: Director
Signature: /s/ Susan Thompson, Attorney-in-Fact
Issuer symbol: BSX
Transactions as of: 02 Mar 2026
Net transactions value: $0
Form type: 4
Filing time: 04 Mar 2026, 19:35:27 UTC
Previous filing: 24 Feb 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Smith Cathy R	Director	300 BOSTON SCIENTIFIC WAY, MARLBOROUGH	/s/ Susan Thompson, Attorney-in-Fact	04 Mar 2026	0001322028

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	BSX	Deferred Stock Units	Award		+556		$0.000000^*	556	02 Mar 2026	Common Stock	556		Direct	F1, F2, F3
transaction	BSX	Deferred Stock Units	Award		+323	+58%	$0.000000^*	879	02 Mar 2026	Common Stock	323		Direct	F1, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.
F2	Grant of deferred stock units to non-employee director following initial appointment to the Board of Directors, which, pursuant to the Company's non-employee director compensation program, has been prorated for the time period from the effective date of the appointment to the date of the Company's 2026 annual meeting of stockholders. The grant of deferred stock units vests in full upon the next annual meeting of stockholders. Reflects a value of approximately $42,419.50 (representing 100% of the prorated amount of the non-employee director compensation program's annual equity award having a value of $215,000) divided by the closing price of the common stock on the date of grant. Vested shares will be issued to the reporting person following the reporting person's separation from Board of Director service, in accordance with the Company's Non-Employee Director Deferred Compensation Plan.
F3	Grant of deferred stock units in lieu of 100% yearly cash compensation following initial appointment to the Board of Directors, which, pursuant to the Company's non-employee director compensation program, has been prorated for the time period from the effective date of the appointment to the date of the Company's 2026 annual meeting of stockholders. The grant of deferred stock units vests in full upon the next annual meeting of stockholders. Reflects a value of approximately $24,662.50 (representing 100% of the prorated amount of the non-employee director compensation program's cash retainer having a value of $125,000) divided by the closing price of the common stock on the date of grant. Vested shares will be issued to the reporting person following the reporting person's separation from Board of Director service, in accordance with the Company's Non-Employee Director Deferred Compensation Plan.